Close menu


The Karolinska Institutet’s Academic Specialist Center (ASC) to Present Results of GeNeuro’s ProTEct-MS Phase 2 Study of Temelimab at ECTRIMS 2022


Geneva, Switzerland, October 25, 2022, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 –GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced it will present Phase IIb safety and efficacy data on temelimab from its ProTEct-MS study at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Amsterdam, Netherlands.


Read the press release

More information